Wednesday Jun 25
The Washington Post
U.S. Stock-Index Futures Little Changed Before Data as IMS Gains
U.S. stock-index futures were little changed, after equities slipped for a second day yesterday, as violence in the Middle East increased, and investors awaited data on durable-goods orders in the world's largest economy.
Press release distribution, EDGAR filing, XBRL, regulatory filings
The corrected release reads: IMMUNOGEN, INC. ANNOUNCES PRECLINICAL FINDINGS FOR IMGN779, A POTENTIAL... )--The International Association of Machinists and Aerospace Workers today announced it reached tentative agreements with US Airways on contracts covering approximat... )--Re: United Utilities Water Plc GBP 100,000,000.00 MATURING: 12-Jul-2057 ... (more)
ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a...
The data were presented at the 19th . IMGN779 is a novel, CD33-targeting, DNA-alkylating ADC that is a potential treatment for acute myeloid leukemia .
Game changers ImmunoGen's breast cancer therapy took time
Patients and doctors applauded last year when the powerful new breast cancer therapy Kadcyla made its market debut, following a long and winding journey to approval for what many view as a miracle medicine.
Immunogen Receives Consensus Rating of "Buy" from Brokerages
Immunogen has earned an average rating of "Buy" from the thirteen brokerages that are presently covering the stock, Analyst Ratings News reports .
Will This Analyst Upgrade Help Immunogen (IMGN) Stock Today?
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.